Skip to main content
Clinical Trials/NCT00703716
NCT00703716
Completed
Not Applicable

Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX

Integra LifeSciences Services10 sites in 1 country190 target enrollmentMay 2008
ConditionsHip Fracture

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hip Fracture
Sponsor
Integra LifeSciences Services
Enrollment
190
Locations
10
Primary Endpoint
The consolidation rate
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the stabilization of trochanteric fracture using a screw-plate TRAUMAX

Detailed Description

Hip fractures are a serious public health problem. The current incidence is projected to increase fourfold worldwide by the year 2050. This affliction is obviously linked to the aging of the population and the absence of a systematic prevention of osteoporosis. This leads to the creation of a minimally invasive, or ever percutaneous, implantable osteosynthesis material which associates : * the well-known reliability of osteosynthesis using screw-plate with barrel, * the safety of the fixation with Surfix concept, locking the screws to the plate using lock-screws, * a modularity thanks to the choice between 3 sizes of barrel, * the creation of a simple material, easing the operative surgery by minimally invasive approach. The TRAUMAX answers to all those characteristics.

Registry
clinicaltrials.gov
Start Date
May 2008
End Date
December 2010
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Integra LifeSciences Services
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Man or woman
  • Age \> 18
  • with a trochanteric fracture whom surgeon advised the use of a screw-plate TRAUMAX

Exclusion Criteria

  • Patient with an acute infection
  • Patient with a major osseous deterioration which not allows a correct support of the screws in the bone
  • Patient with an ASA score of 4 or 5
  • Patient whom the time between the fracture and the surgery could be higher than 8 days

Outcomes

Primary Outcomes

The consolidation rate

Time Frame: 6 months after surgery

The rate of complication due to the device

Time Frame: 6 months after surgery

Secondary Outcomes

  • operating time(during the surgery)
  • PMA score(3 and 6 months after surgery)
  • The duration of the use of the amplifier of brilliancy during the intervention(during the surgery)
  • The radiological position of the device(5 days, 3 and 6 months)
  • The evolution of the functional scores (Parker, ADL, Katz, Robinson) between before the fracture and after the intervention.(3 and 6 months after surgery)

Study Sites (10)

Loading locations...

Similar Trials